Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL712757

CCOC(=O)c1cnc2[nH]c(-c3cc(OCCCc4cccnc4)cc(OC(C)C)c3)nc2c1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 4/20 0.46
PTAFR P25105 2/20 0.37
TBXAS1 P24557 1/20 0.37
CDC7 O00311 1/20 0.37
DBF4 Q9UBU7 1/20 0.37
HCRTR1 O43613 1/20 0.37
MAOB P27338 1/20 0.36
POLB P06746 1/20 0.35
HPGD P15428 1/20 0.35
MAPT P10636 2/20 0.35
TP53 P04637 1/20 0.35
APAF1 O14727 1/20 0.35
PABPC1 P11940 1/20 0.35
CASP6 P55212 1/20 0.35
CASP8 Q14790 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GRM2 Q14416 1/20 0.35
PKN1 Q16512 1/20 0.34
PKN2 Q16513 1/20 0.34
SERPINE1 P05121 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10206505 0.95 GCK (0.48) GCKPTAFRTBXAS1HCRTR1MAOB
Trifluoroacetic Acid SCHEMBL710573 0.92 GCK (0.52) GCKPTAFRTBXAS1POLBHPGD
Trifluoroacetic Acid SCHEMBL711785 0.88 GCK (0.45) GCKPTAFRTBXAS1HCRTR1APAF1
SCHEMBL10206513 0.88 GCK (0.56) GCKPTAFRTBXAS1POLBHPGD
SCHEMBL709520 0.82 GCK (0.49) GCKMAOBHPGDMAPTTP53
SCHEMBL711135 0.81 PKN1 (0.42) GCKMAOBMAPTTP53PKN1
SCHEMBL2668116 0.81 GCK (0.44) GCKPTAFRTBXAS1HPGDGRM2
SCHEMBL711044 0.80 GCK (0.46) GCKPTAFRTBXAS1POLBHPGD
Trifluoroacetic Acid SCHEMBL709569 0.80 DHODH (0.43) GCKHCRTR1POLBHPGDAPAF1
Trifluoroacetic Acid SCHEMBL720615 0.79 GCK (0.45) GCKMAPTTP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK GCK 1/4885PTAFR 2810/4885TBXAS1 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.